News & Resources
Financial Results for year ended 30 September 2025 and Notice of AGM
09 December 2025, IXICO plc (AIM: IXI) - London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, announces its audited results for the year ended 30 September 2025 ("FY25").
Execution of the Group's Innovate Lead Scale strategy across the year has delivered a strong financial performance with 13% revenue growth and a 21% reduction in EBITDA loss. Commercial traction has further accelerated into FY26, resulting in a 27% increase to the order book since the FY25 year-end.
AI-Driven Recruitment for Alzheimer’s Disease Clinical Trials: A Pilot Analysis on the A4 Study Dataset
Efficient recruitment in Alzheimer’s disease (AD) trials is challenging, and early use of sensitive biomarkers can reduce screen failures and costs. We evaluated an MRI-based machine learning model, previously trained to classify AD, FTD, normal controls, and other dementias, as a pre-screening tool using A4 Study data.
IXICO strengthens Scientific Advisory Board with two prominent global Alzheimer’s Disease and vascular experts
01 December 2025, IXICO plc (AIM: IXI) – London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announced that it has appointed two leading global experts in the field of Alzheimer’s Disease (AD) and cerebrovascular disease (CVD) as advisors to the Company. Professor Michael Weiner, and Professor Joanna Wardlaw join IXICO’s advisory board with immediate effect.
Exploring how GLP-1 Drugs and vascular biomarkers are shaping Alzheimer’s Disease clinical trial design
At CTAD 2025, all eyes will be on GLP-1 therapies as Novo Nordisk shares new data from its semaglutide Alzheimer’s programme.
The Emergence of Neuromelanin-Sensitive Imaging in Parkinson’s Clinical Trials
Neuromelanin-sensitive magnetic resonance imaging (NM-MRI) has emerged as a promising biomarker for Parkinson’s disease (PD) research. Historically, imaging in PD has relied primarily on nuclear medicine techniques such as dopamine transporter (DAT) scans, as patients with PD do not exhibit robust, disease-specific patterns of brain atrophy detectable with conventional structural MRI.
Global Phase 3 Clinical Trial Contract Win
17 November 2025 IXICO plc (AIM: IXI) – London, UK. IXICO, a global leader in neuroscience precision medicine and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announced that it has signed a new commercial contract with a global pharmaceutical company to provide imaging services for a worldwide Phase 3 clinical trial in Huntington’s Disease (HD). The total contract value is over £3.5m over four years.
Capital Markets Day Presentation and Video 2025
Capital Markets Day Presentation and Video 03 November 2025 IXICO plc (AIM: IXI) – London, UK.
Advancing AD Trials: Integrating Plasma Biomarkers and Imaging for Precision Enrolment
The development of blood-based biomarkers (BBMs) for early detection of Alzheimer’s disease (AD) pathology is transformative for research and drug development. Historically, diagnosis relied on symptomatic presentation with costly confirmatory imaging. Today, the field is shifting toward a biologically defined framework for earlier detection and trial stratification.
1-8 of 183 results